Executive Summary
The single contract in this period, a $240.6 million firm-fixed-price delivery order from the Department of Veterans Affairs to QTC Medical Services Inc. (a Leidos Holdings subsidiary), is entirely civilian and represents a near-fully funded, competitive win for medical evaluation services.
The signal is neutral, as the contract is a one-year, non-optioned award with 97% of funding already outlayed, indicating execution is largely complete. The key risk is the lack of follow-on visibility beyond September 2024, while the bullish takeaway is Leidos’s ability to secure a large, competitive VA contract in a stable healthcare services budget environment. No defense-related contracts were awarded, underscoring a civilian-only procurement stream for this period.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from September 20, 2026.
Investment Signals (1)
- Leidos (QTC Medical) Wins $240.6M VA Medical Evaluation Contract, Fully Funded (HIGH)▲
Leidos subsidiary QTC Medical Services secured a $240.6M firm-fixed-price delivery order from the VA for physician-based medical evaluation/screening services (FY24). With $233.6M already outlayed (97% of total), the contract is near completion, signaling strong execution but limited upside from this specific award.
Risk Flags (2)
- Concentration [MEDIUM RISK]▼
Leidos’s reliance on a single, fully funded one-year VA contract with no options creates a revenue cliff after September 2024. The absence of follow-on task orders or extensions raises execution risk for maintaining VA healthcare services revenue.
- Competition [MEDIUM RISK]▼
Awarded under full and open competition with no set-aside, this contract signals that Leidos faces direct competition from other healthcare services providers. Any re-compete could erode margins or result in loss of the contract.
Opportunities (1)
- ◆
The VA’s sustained $240M+ annual spending on medical evaluation services under NAICS 621111 suggests a stable, recurring budget line. Leidos can leverage its incumbent position to bid on future VA task orders or expand into other civilian agency healthcare contracts (e.g., HHS, DOL).
Sector Themes (1)
- ◆
The VA’s full funding of a $240.6M medical evaluation contract with 97% outlayed demonstrates predictable, non-discretionary spending on physician-based services. This contrasts with defense procurement volatility under continuing resolutions.
Watch List (2)
- 👁
{"entity" => "Leidos Holdings (LDOS)", "reason" => "The $240.6M VA contract is a material civilian revenue stream, but its one-year duration and near-complete funding create a gap in forward visibility. Any re-compete win or new VA award would be a positive catalyst.", "trigger" => "VA announcement of follow-on contract for medical evaluation services (expected post-Sep 2024)"}
- 👁
{"entity" => "Department of Veterans Affairs healthcare services budget", "reason" => "VA’s continued spending on medical evaluations is a bellwether for civilian healthcare procurement trends. A budget cut or shift to in-house services would negatively impact contractors like Leidos.", "trigger" => "FY25 VA budget request or appropriations bill"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
September 19, 2026
Significant Contract Modifications ($10M+) — September 19, 2026
September 17, 2026
Significant Contract Modifications ($10M+) — September 17, 2026
September 16, 2026
Significant Contract Modifications ($10M+) — September 16, 2026
September 13, 2026
Significant Contract Modifications ($10M+) — September 13, 2026
🇺🇸 More from United States
View all →September 22, 2026
USA Corporate Events Calendar — September 22, 2026
USA Corporate Events Calendar
September 22, 2026
High-Value Federal Grants ($5M+) — September 22, 2026
High-Value Federal Grants ($5M+)
September 22, 2026
US SEC Trading Suspension Halt Orders — September 22, 2026
US SEC Trading Suspension Halt Orders
September 22, 2026
US Executive Compensation Proxy SEC Filings — September 22, 2026
US Executive Compensation Proxy SEC Filings